Skip Navigation


Brain Advance Access originally published online on December 2, 2006
Brain 2007 130(1):110-119; doi:10.1093/brain/awl319
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrowOA All Versions of this Article:
130/1/110    most recent
awl319v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (16)
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Chinnery, P. F.
Right arrow Articles by Burn, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Chinnery, P. F.
Right arrow Articles by Burn, J.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 2006 The Author(s)
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/2.0/uk/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.

Clinical features and natural history of neuroferritinopathy caused by the FTL1 460InsA mutation

Patrick F. Chinnery1,2, Douglas E. Crompton1,2, Daniel Birchall3, Margaret J. Jackson2, Alan Coulthard3,8, Anne Lombès9, Niall Quinn4, Adrian Wills5, Nicholas Fletcher6, John P. Mottershead7, Paul Cooper7, Mark Kellett7, David Bates2 and John Burn1

1 Institute of Human Genetics, University of Newcastle upon Tyne UK 2 Department of Neurology, University of Newcastle upon Tyne UK 3 Department of Neuroradiology, Regional Neurosciences Centre Newcastle Upon Tyne Hospitals NHS Trust, Newcastle upon Tyne, UK 4 Institute of Neurology Queen Square, London 5 Queens Medical Centre Nottingham, UK 6 The Walton Centre for Neurology and Neurosurgery Liverpool, UK 7 Greater Manchester Centre for Clinical Neurosciences Hope Hospital, Salford, UK 8 Department of Medical Imaging, University of Queensland Royal Brisbane and Women's Hospital, Brisbane, Australia 9 Institut National de la Santé et de la Recherche Médicale U582, Paris, France

Correspondence to: Professor Patrick F. Chinnery, The Medical School, Framlington Place, Newcastle upon Tyne, NE2 4HH, UK Email: p.f.chinnery{at}ncl.ac.uk

Neuroferritinopathy is a progressive potentially treatable adult-onset movement disorder caused by mutations in the ferritin light chain gene (FTL1). Features overlap with common extrapyramidal disorders: idiopathic torsion dystonia, idiopathic Parkinson's disease and Huntington's disease, but the phenotype and natural history have not been defined. We studied a genetically homogeneous group of 41 subjects with the 460InsA mutation in FTL1, documenting the presentation, clinical course, biochemistry and neuroimaging. The mean age of onset was 39.4 years (SD = 13.3, range 13–63), beginning with chorea in 50%, focal lower limb dystonia in 42.5% and parkinsonism in 7.5%. The majority reported a family history of a movement disorder often misdiagnosed as Huntington's disease. The disease progressed relentlessly, becoming generalized over a 5–10 year period, eventually leading to aphonia, dysphagia and severe motor disability with subcortical/frontal cognitive dysfunction as a late feature. A characteristic action-specific facial dystonia was common (65%), and in 63% there was asymmetry throughout the disease course. Serum ferritin levels were low in the majority of males and post-menopausal females, but within normal limits for pre-menopausal females. MR brain imaging was abnormal on all affected individuals and one presymptomatic carrier. In conclusion, isolated parkinsonism is unusual in neuroferritinopathy, and unlike Huntington's disease, cognitive changes are absent or subtle in the early stages. Depressed serum ferritin is common and provides a useful screening test in routine practice, and gradient echo brain MRI will identify all symptomatic cases.

Key Words: chorea; dystonia; ferritin; iron; movement disorder; neurodegeneration; neuroferritinopathy

Abbreviations: FTL1, ferritin light chain gene; ITD, idiopathic torsion dystonia; PANK2, pantothenate kinase 2

Received August 23, 2006. Accepted October 16, 2006.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
BrainHome page
D. Devos, P. J. Tchofo, I. Vuillaume, A. Destee, S. Batey, J. Burn, and P. F. Chinnery
Clinical features and natural history of neuroferritinopathy caused by the 458dupA FTL mutation
Brain, June 1, 2009; 132(6): e109 - e109.
[Full Text] [PDF]


Home page
NeurologyHome page
E. E. Benarroch
Brain iron homeostasis and neurodegenerative disease
Neurology, April 21, 2009; 72(16): 1436 - 1440.
[Full Text] [PDF]


Home page
NeurologyHome page
A. McNeill, D. Birchall, S. J. Hayflick, A. Gregory, J. F. Schenk, E. A. Zimmerman, H. Shang, H. Miyajima, and P. F. Chinnery
T2* and FSE MRI distinguishes four subtypes of neurodegeneration with brain iron accumulation
Neurology, April 29, 2008; 70(18): 1614 - 1619.
[Abstract] [Full Text] [PDF]


Home page
NeurologyHome page
E. Ohta, T. Nagasaka, K. Shindo, S. Toma, K. Nagasaka, K. Ohta, and Z. Shiozawa
NEUROFERRITINOPATHY IN A JAPANESE FAMILY WITH A DUPLICATION IN THE FERRITIN LIGHT CHAIN GENE
Neurology, April 15, 2008; 70(16_Part_2): 1493 - 1494.
[Full Text] [PDF]


Home page
PNHome page
E J Wild and S J Tabrizi
The differential diagnosis of chorea
Practical Neurology, November 1, 2007; 7(6): 360 - 373.
[Abstract] [Full Text] [PDF]



Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.